-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Awarded the National-Level Manufacturing Single-Champion Title
Category:
发布时间：2022-11-28
【概要描述】
Recently, the Ministry of Industry and Information Technology of the People’s Republic of China and the China Federation of Industrial Economics announced the seventh batch of Manufacturing Single-Champion Enterprises (Products), with Shijiazhuang Sihua Pharmaceutical Co., Ltd. recognized as a Manufacturing Single-Champion.
Recently, the Ministry of Industry and Information Technology of the People’s Republic of China and the China Federation of Industrial Economics announced the seventh batch of Manufacturing Single-Champion Enterprises (Products), with Shijiazhuang Sihua Pharmaceutical Co., Ltd. recognized as a Manufacturing Single-Champion.
A “Manufacturing Single-Champion” refers to an enterprise or product that has long been focused on specific niche segments of the manufacturing market, boasts internationally leading production technologies or processes, and ranks among the global leaders in market share for its particular product. Cultivating such champions is a key component of promoting high-quality development in the manufacturing sector. Since 2016, the Ministry of Industry and Information Technology has conducted seven rounds of selection for Manufacturing Single-Champion Enterprises (and Products).
“The Single-Item Champion” is hailed as the “pearl” atop the crown of manufacturing, serving as a crucial benchmark for assessing a company’s market share in a specific product category and its level of technological innovation. As a leading domestic enterprise in the production, R&D, and export of injectable formulations, Shijiazhuang Sihua Pharmaceutical leverages its industrial strengths to align its industrial chain with the innovation chain and enhance the value chain through the industrial chain. The company actively develops and applies new, iterative products that offer high added value and strong market growth potential, has proposed and participated in the formulation of more than 90 relevant quality and technical standards and patents, and, by capitalizing on its leading role in the development of the intravenous infusion industry, has effectively spurred the industrial application and large-scale production of soft-packaged infusions. In recent years, sales and production of Shijiazhuang Sihua’s soft-bag infusion products have maintained rapid growth, capturing roughly half of the domestic market and being exported to over 90 countries and regions worldwide, thereby powerfully driving the transformation and upgrading of the company’s flagship products.
“Single-item champions” cannot be achieved without the support of core technologies. Shijiazhuang Sihua Pharmaceutical has kept its focus firmly on transformation, upgrading, quality improvement, and efficiency enhancement. By attracting and recruiting high-caliber innovation talent, the company has continuously advanced efforts to extend, supplement, and strengthen industrial chains, as well as to innovate in core technology products. It has also devoted itself to overcoming critical “bottleneck” technologies. Its project, “Establishment and Application of a Quality Control Technology System for Soft-Packaged Large-Volume Infusions,” was awarded the First Prize for Scientific and Technological Progress by Hebei Province. Meanwhile, the industrial chain structure—encompassing generic drugs, innovative drugs, specialty APIs, and pharmaceutical packaging materials—has been steadily optimized and upgraded. In the first ten months of this year, Shijiazhuang Sihua Pharmaceutical ranked among the top in the nation in terms of the number of approved and submitted applications for its specialty generic drugs, thereby continuously empowering the company’s high-quality development. Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical, stated that the company will seize the new opportunity presented by Shijiazhuang to achieve breakthroughs in the biopharmaceutical industry ahead of others, leverage the leading role of scientific and technological innovation, accelerate product innovation and the commercialization of research outcomes, and continually cultivate and create more “single-item champion products.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091